Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea

COVID-19 Vaccine Safety Research Committee

doi:10.3346/jkms.2024.39.e309

Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea

COVID-19 Vaccine Safety Research Committee

Department of Preventive Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20, 180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

Original language	English
Article number	e309
Journal	Journal of Korean Medical Science
Volume	39
Issue number	43
DOIs	https://doi.org/10.3346/jkms.2024.39.e309
State	Published - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Korean Academy of Medical Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords

COVID-19
Korea Disease Control and Prevention Agency
Omicron
Safety
Vaccination
XBB.1.5 Variant

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3346/jkms.2024.39.e309

Cite this

@article{9f3844d2297341c8bb86bac12b06c172,

title = "Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea",

abstract = "The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20, 180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.",

keywords = "COVID-19, Korea Disease Control and Prevention Agency, Omicron, Safety, Vaccination, XBB.1.5 Variant",

author = "{COVID-19 Vaccine Safety Research Committee} and Bomi Park and Lee, {Hye Ah} and Yeonjae Kim and Kim, {Chung Ho} and Hyunjin Park and Seunghee Jun and Hyelim Lee and Kwon, {Seunghyun Lewis} and Yesul Heo and Hyungmin Lee and Hyesook Park",

note = "Publisher Copyright: {\textcopyright} 2024 The Korean Academy of Medical Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",

year = "2024",

doi = "10.3346/jkms.2024.39.e309",

language = "English",

volume = "39",

journal = "Journal of Korean Medical Science",

issn = "1011-8934",

publisher = "Korean Academy of Medical Science",

number = "43",

}

TY - JOUR

T1 - Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea

AU - COVID-19 Vaccine Safety Research Committee

AU - Park, Bomi

AU - Lee, Hye Ah

AU - Kim, Yeonjae

AU - Kim, Chung Ho

AU - Park, Hyunjin

AU - Jun, Seunghee

AU - Lee, Hyelim

AU - Kwon, Seunghyun Lewis

AU - Heo, Yesul

AU - Lee, Hyungmin

AU - Park, Hyesook

N1 - Publisher Copyright: © 2024 The Korean Academy of Medical Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2024

Y1 - 2024

N2 - The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20, 180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

AB - The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20, 180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

KW - COVID-19

KW - Korea Disease Control and Prevention Agency

KW - Omicron

KW - Safety

KW - Vaccination

KW - XBB.1.5 Variant

UR - http://www.scopus.com/inward/record.url?scp=85209407164&partnerID=8YFLogxK

U2 - 10.3346/jkms.2024.39.e309

DO - 10.3346/jkms.2024.39.e309

M3 - Article

C2 - 39536790

AN - SCOPUS:85209407164

SN - 1011-8934

VL - 39

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

IS - 43

M1 - e309

ER -

Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this